Akoya Biosciences (AKYA) Stock Forecast, Price Target & Predictions
AKYA Stock Forecast
Akoya Biosciences stock forecast is as follows: an average price target of $5.30 (represents a 145.37% upside from AKYA’s last price of $2.16) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AKYA Price Target
The average price target for Akoya Biosciences (AKYA) is $5.30 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $7.50 to $3.00. This represents a potential 145.37% upside from AKYA's last price of $2.16.
AKYA Analyst Ratings
According to 5 Wall Street analysts, Akoya Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for AKYA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Akoya Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Dave Westenberg | Piper Sandler | $4.00 | $2.32 | 72.41% | 85.19% |
| Aug 06, 2024 | Tejas Savant | Morgan Stanley | $3.00 | $2.01 | 49.25% | 38.89% |
| Jun 21, 2024 | Bill Bonello | Craig-Hallum | $7.50 | $2.23 | 236.32% | 247.22% |
| Jun 03, 2024 | Tejas Savant | Morgan Stanley | $4.00 | $2.15 | 86.05% | 85.19% |
| May 14, 2024 | Mark Massaro | BTIG | $6.00 | $4.12 | 45.63% | 177.78% |
| May 14, 2024 | Kyle Mikson | Canaccord Genuity | $6.00 | $4.12 | 45.63% | 177.78% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $17.00 | $13.34 | 27.44% | 687.04% |
The latest Akoya Biosciences stock forecast, released on Nov 15, 2024 by Dave Westenberg from Piper Sandler, set a price target of $4.00, which represents a 72.41% increase from the stock price at the time of the forecast ($2.32), and a 85.19% increase from AKYA last price ($2.16).
Akoya Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 6 |
| Avg Price Target | $4.00 | $4.00 | $5.08 |
| Last Closing Price | $2.16 | $2.16 | $2.16 |
| Upside/Downside | 85.19% | 85.19% | 135.19% |
In the current month, the average price target of Akoya Biosciences stock is $4.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 85.19% increase as opposed to Akoya Biosciences's last price of $2.16. This month's average price target is down 0.00% compared to last quarter, and down -21.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Aug 06, 2024 | BTIG | Buy | Neutral | Downgrade |
| Jun 21, 2024 | Craig-Hallum | - | Buy | Initialise |
| Jun 03, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 14, 2024 | BTIG | Buy | Buy | Hold |
| May 14, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jan 04, 2023 | BTIG | Buy | Buy | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Akoya Biosciences's last stock rating was published by Morgan Stanley on Aug 06, 2024. The company Downgrade its AKYA rating from "Overweight" to "Equal-Weight".
Akoya Biosciences Financial Forecast
Akoya Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $26.49M | $25.21M | $23.52M | $21.41M | $21.22M | $18.85M | $17.89M | $16.89M | $16.16M | $13.48M | $13.07M | $12.21M |
| Avg Forecast | $34.61M | $31.38M | $28.50M | $25.30M | $28.21M | $25.10M | $23.74M | $21.24M | $23.79M | $25.29M | $23.43M | $24.35M | $26.14M | $24.51M | $22.39M | $20.32M | $20.47M | $17.59M | $16.92M | $14.93M | $15.52M | $13.06M | $12.59M | $12.03M |
| High Forecast | $39.27M | $35.61M | $32.35M | $28.72M | $32.01M | $28.49M | $26.95M | $23.62M | $25.10M | $25.51M | $23.49M | $24.35M | $26.25M | $24.51M | $25.41M | $23.05M | $23.22M | $17.59M | $16.92M | $14.93M | $15.52M | $13.06M | $12.59M | $12.03M |
| Low Forecast | $31.96M | $28.98M | $26.32M | $23.37M | $26.05M | $23.18M | $21.93M | $19.84M | $22.14M | $25.08M | $23.37M | $24.35M | $26.02M | $24.51M | $20.68M | $18.76M | $18.90M | $17.59M | $16.92M | $14.93M | $15.52M | $13.06M | $12.59M | $12.03M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.03% | 1.05% | 1.05% | 1.04% | 1.07% | 1.06% | 1.13% | 1.04% | 1.03% | 1.04% | 1.02% |
Akoya Biosciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $24.35M, with a low forecast of $24.35M, and a high forecast of $24.35M. AKYA's average Quarter revenue forecast represents a -8.09% decrease compared to the company's last Quarter revenue of $26.49M (Dec 23).
Akoya Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-11.20M | $-12.79M | $-16.23M | $-14.52M | $-14.80M | $-14.57M | $-16.08M | $-13.81M | $-21.87M | $-9.62M | $-3.68M | $-6.30M |
| Avg Forecast | $-16.37M | $-14.84M | $-13.48M | $-11.97M | $-13.34M | $-11.87M | $-11.23M | $-10.04M | $-11.25M | $-11.96M | $-11.08M | $-11.51M | $-12.36M | $-11.59M | $-10.59M | $-9.61M | $-9.68M | $-8.15M | $-7.84M | $-12.21M | $-7.19M | $-6.05M | $-5.83M | $-106.66M |
| High Forecast | $-15.12M | $-13.71M | $-12.45M | $-11.05M | $-12.32M | $-10.96M | $-10.37M | $-9.38M | $-10.47M | $-11.86M | $-11.05M | $-11.51M | $-12.30M | $-11.59M | $-9.78M | $-8.87M | $-8.94M | $-8.15M | $-7.84M | $-9.77M | $-7.19M | $-6.05M | $-5.83M | $-85.33M |
| Low Forecast | $-18.57M | $-16.84M | $-15.30M | $-13.58M | $-15.14M | $-13.47M | $-12.74M | $-11.17M | $-11.87M | $-12.06M | $-11.11M | $-11.51M | $-12.41M | $-11.59M | $-12.02M | $-10.90M | $-10.98M | $-8.15M | $-7.84M | $-14.66M | $-7.19M | $-6.05M | $-5.83M | $-127.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.10% | 1.53% | 1.51% | 1.53% | 1.79% | 2.05% | 1.13% | 3.04% | 1.59% | 0.63% | 0.06% |
undefined analysts predict AKYA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akoya Biosciences's previous annual EBITDA (undefined) of $NaN.
Akoya Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-10.80M | $-12.92M | $-20.80M | $-18.80M | $-18.88M | $-17.87M | $-17.50M | $-16.40M | $-17.67M | $-11.62M | $-5.56M | $-8.08M |
| Avg Forecast | $495.03K | $-1.73M | $-4.46M | $-9.90M | $-4.62M | $-6.44M | $-7.92M | $-10.31M | $-7.28M | $-9.90M | $-13.19M | $-14.29M | $-13.31M | $-17.68M | $-21.80M | $-23.70M | $-21.46M | $-21.72M | $-18.38M | $-14.30M | $-15.28M | $-12.85M | $-11.43M | $-136.92M |
| High Forecast | $581.77K | $-1.56M | $-4.01M | $-8.92M | $-4.16M | $-5.80M | $-7.13M | $-6.09M | $-3.64M | $-8.92M | $-11.88M | $-12.87M | $-12.32M | $-15.92M | $-19.63M | $-21.34M | $-19.33M | $-21.72M | $-18.38M | $-11.44M | $-15.28M | $-12.85M | $-11.43M | $-109.53M |
| Low Forecast | $445.79K | $-2.04M | $-5.24M | $-11.64M | $-5.43M | $-7.56M | $-9.31M | $-12.66M | $-10.93M | $-11.64M | $-15.50M | $-16.80M | $-14.29M | $-20.78M | $-25.61M | $-27.85M | $-25.22M | $-21.72M | $-18.38M | $-17.16M | $-15.28M | $-12.85M | $-11.43M | $-164.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.73% | 0.95% | 0.79% | 0.88% | 0.82% | 0.95% | 1.15% | 1.16% | 0.90% | 0.49% | 0.06% |
Akoya Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKYA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Akoya Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $18.90M | $19.02M | $22.71M | $21.76M | $20.95M | $19.92M | $20.59M | $18.19M | $19.05M | $13.72M | $10.07M | $8.18M |
| Avg Forecast | $27.93M | $25.32M | $23.00M | $20.42M | $22.76M | $20.26M | $19.16M | $17.14M | $19.19M | $20.41M | $18.90M | $19.64M | $21.09M | $19.78M | $18.07M | $16.39M | $16.51M | $14.19M | $13.65M | $12.04M | $12.52M | $10.54M | $10.16M | $9.71M |
| High Forecast | $31.69M | $28.73M | $26.10M | $23.17M | $25.83M | $22.99M | $21.74M | $19.06M | $20.25M | $20.58M | $18.95M | $19.64M | $21.18M | $19.78M | $20.50M | $18.60M | $18.74M | $14.19M | $13.65M | $12.04M | $12.52M | $10.54M | $10.16M | $9.71M |
| Low Forecast | $25.79M | $23.38M | $21.24M | $18.86M | $21.02M | $18.71M | $17.69M | $16.01M | $17.86M | $20.24M | $18.86M | $19.64M | $20.99M | $19.78M | $16.69M | $15.14M | $15.25M | $14.19M | $13.65M | $12.04M | $12.52M | $10.54M | $10.16M | $9.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.96% | 1.26% | 1.33% | 1.27% | 1.40% | 1.51% | 1.51% | 1.52% | 1.30% | 0.99% | 0.84% |
Akoya Biosciences's average Quarter SG&A projection for Mar 24 is $19.64M, based on 4 Wall Street analysts, with a range of $19.64M to $19.64M. The forecast indicates a 3.95% rise compared to AKYA last annual SG&A of $18.90M (Dec 23).
Akoya Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.26 | $-0.51 | $-0.49 | $-0.50 | $-0.47 | $-0.47 | $-0.44 | $-0.47 | $-0.31 | $-0.20 | $-0.23 |
| Avg Forecast | $0.01 | $-0.04 | $-0.09 | $-0.20 | $-0.09 | $-0.13 | $-0.16 | $-0.21 | $-0.15 | $-0.20 | $-0.27 | $-0.29 | $-0.27 | $-0.36 | $-0.44 | $-0.48 | $-0.43 | $-0.44 | $-0.37 | $-0.39 | $-0.31 | $-0.26 | $-0.23 | $-0.17 |
| High Forecast | $0.01 | $-0.03 | $-0.08 | $-0.18 | $-0.08 | $-0.12 | $-0.14 | $-0.12 | $-0.07 | $-0.18 | $-0.24 | $-0.26 | $-0.25 | $-0.32 | $-0.40 | $-0.43 | $-0.39 | $-0.44 | $-0.37 | $-0.39 | $-0.31 | $-0.26 | $-0.23 | $-0.17 |
| Low Forecast | $0.01 | $-0.04 | $-0.11 | $-0.24 | $-0.11 | $-0.15 | $-0.19 | $-0.26 | $-0.22 | $-0.24 | $-0.31 | $-0.34 | $-0.29 | $-0.42 | $-0.52 | $-0.56 | $-0.51 | $-0.44 | $-0.37 | $-0.39 | $-0.31 | $-0.26 | $-0.23 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.73% | 1.16% | 1.02% | 1.15% | 1.07% | 1.26% | 1.14% | 1.52% | 1.19% | 0.86% | 1.35% |
According to undefined Wall Street analysts, Akoya Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKYA previous annual EPS of $NaN (undefined).
Akoya Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $99.08 | $298.00 | 200.77% | Buy |
| AKYA | Akoya Biosciences | $2.16 | $5.30 | 145.37% | Buy |
| ANGO | AngioDynamics | $6.74 | $15.00 | 122.55% | Buy |
| ATRC | AtriCure | $36.03 | $49.57 | 37.58% | Buy |
| HAE | Haemonetics | $84.92 | $108.25 | 27.47% | Buy |
| ICUI | ICU Medical | $167.59 | $172.00 | 2.63% | Buy |
| LMAT | LeMaitre Vascular | $103.44 | $85.25 | -17.59% | Buy |
| ATR | AptarGroup | $168.73 | $138.00 | -18.21% | Buy |